×
About 1,115 results

ALLMedicine™ Central Retinal Vein Occlusion Center

Research & Reviews  378 results

Combination of Ranibizumab and Targeted Laser Photocoagulation
https://clinicaltrials.gov/ct2/show/NCT04444492

May 11th, 2022 - Retinal vein occlusion (RVO) is the second most common retinal vascular disease leading to visual impairment. Main cause for visual impairment in CRVO (Central Retinal Vein Occlusion) is macular edema (ME) while neovascularization of the retina an...

Retinal vascular occlusion in pregnancy: three case reports and a review of the literat...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022314
Journal of Medical Case Reports; Jürgens L, Yaici R et. al.

Apr 23rd, 2022 - Retinal arterial occlusive events in young patients are rare. However, because of physiological multifactorial adaptations during pregnancy, retinal vascular occlusive disease may occur spontaneously. In addition, a patent foramen ovale is a risk ...

Analysis on short-term change of macular function and the correlates after intravitreal...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994389
BMC Ophthalmology; Wang YC, Li RR et. al.

Apr 10th, 2022 - To study the short-term change of macular function and the correlates after intravitreal conbercept for CRVO-ME. Prospective, clinical study. Twenty Three patients(23 eyes) were recruited, who were non-ischemia central retinal vein occlusion diagn...

Retinal non-perfusion in the ETDRS seven fields compared with widefield fluorescein ang...
https://doi.org/10.1097/IAE.0000000000003498
Retina (Philadelphia, Pa.); Martin-Gutierrez MP, Vermeirsch S et. al.

Apr 8th, 2022 - In previous landmark studies on central retinal vein occlusion (CRVO), retinal non-perfusion assessments were obtained using 7-field (7F) angiography. The widespread current use of widefield (WF) imaging allows better visualization of the peripher...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  29 results

Combination of Ranibizumab and Targeted Laser Photocoagulation
https://clinicaltrials.gov/ct2/show/NCT04444492

May 11th, 2022 - Retinal vein occlusion (RVO) is the second most common retinal vascular disease leading to visual impairment. Main cause for visual impairment in CRVO (Central Retinal Vein Occlusion) is macular edema (ME) while neovascularization of the retina an...

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
https://clinicaltrials.gov/ct2/show/NCT03810313

Jan 19th, 2022 - Following a 4-week maximum screening period, patients will be randomized and treated for approximately 76 weeks. Treatment visits will be scheduled in 4-week intervals. After 6 initial monthly injections of brolucizumab or aflibercept (loading pha...

Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment
https://clinicaltrials.gov/ct2/show/NCT04707625

Jan 6th, 2022 - Ten patients, 5 with branch retinal vein occlusion and 5 with central retinal vein occlusion, will receive stand of care anti-vascular endothelial growth factor over the course of 52 weeks while undergoing a paracentesis prior to each treatment. D...

Treatment of Central Retinal Vein Occlusion Using Stem Cells Study
https://clinicaltrials.gov/ct2/show/NCT03981549

Sep 13th, 2021 - The goal of this phase I/II prospective, randomized, sham-controlled, double-masked clinical trial is to determine whether intravitreal autologous CD34+ stem cell therapy is safe, feasible and potentially beneficial in eyes with vision loss from c...

Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion
https://clinicaltrials.gov/ct2/show/NCT04812977

Mar 24th, 2021 - To compare the effect of intravitreal-Bevacizumab and Triamcinolone with intravitreal-Bevacizumab alone on visual acuity and central foveal thickness in patients with macular edema secondary to central retinal vein occlusion.

see more →

News  38 results

FDA OKs Aflibercept (Eylea) for Diabetic Retinopathy
https://www.medscape.com/viewarticle/913006

May 14th, 2019 - The US Food and Drug Administration (FDA) has approved aflibercept (Eylea, Regeneron) injection solution to treat all stages of diabetic retinopathy, the manufacturer has announced. Aflibercept, a vascular endothelial growth factor (VEGF) inhibito...

FDA Okays Aflibercept (Eylea) for Diabetic Retinopathy
https://www.staging.medscape.com/viewarticle/913006

May 14th, 2019 - The US Food and Drug Administration (FDA) has approved aflibercept (Eylea, Regeneron Pharmaceuticals) injection solution to treat all stages of diabetic retinopathy, the manufacturer has announced. Aflibercept, a vascular endothelial growth factor...

Sustained Drug-Delivery Tech Shows Promise
https://www.medpagetoday.com/ophthalmology/generalophthalmology/69384

Nov 19th, 2017 - Development of technologies for sustained drug delivery is a topic of great interest among retina specialists, considering the number of chronic conditions that are managed with repeated intravitreal injections. Products in this category are alrea...

An Elderly Patient's Blurry Right Eye Raises Questions
https://www.medscape.com/viewarticle/882951_2

Jul 24th, 2017 - Case Diagnosis Isolated chronic elevation of the optic disc with relatively preserved visual function raises suspicion for vitreopapillary traction (VPT). This diagnosis can be confirmed by OCT, as it was in this patient. Idiopathic intracranial h...

Despite Significantly Different Pricing, Similar Efficacy for Key Anti-VEGF Agents in Macular Edema
https://www.medscape.com/viewarticle/881454

Jun 20th, 2017 - Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial Scott IU, VanVeldhuisen PC, Ip MS, et al; SCORE2 Investigator Group JAMA. 2017; 317...

see more →